Praxis Precision Medicines' movement disorder drug shows promise in trials
PraxisPraxis(US:PRAX) Reuters·2025-10-16 11:09

Core Insights - Praxis Precision Medicines announced that its experimental drug for movement disorders has shown positive results in improving daily functioning for patients in two late-stage trials [1] Company Summary - The company is focused on developing treatments for movement disorders and has reached significant milestones in its clinical trials [1]